Study S002284

Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07011667
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 609
Start: 2025-06-03
Primary completion: 2027-03-01
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:CagriSema (Cagrilintide B and Semaglutide I); DRUG:Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1318-6372

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to week 80]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.